For help on how to get the results you want, see our search tips.
1703 results
Medicine
Orphan designations Remove Orphan designations filter
Shortages Remove Shortages filter
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Orladeyo (updated)
berotralstat dihydrochloride, Angioedemas, Hereditary
Date of authorisation: 30/04/2021, Revision: 5, Authorised, Last updated: 01/12/2023 -
List item
Human medicine European public assessment report (EPAR): Semglee (updated)
insulin glargine, Diabetes Mellitus
Date of authorisation: 23/03/2018,
, Revision: 10, Authorised, Last updated: 01/12/2023
-
List item
Human medicine European public assessment report (EPAR): Ogivri (updated)
trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 12/12/2018,, Revision: 11, Authorised, Last updated: 01/12/2023
-
List item
Human medicine European public assessment report (EPAR): Kirsty (previously Kixelle) (updated)
insulin aspart, Diabetes Mellitus
Date of authorisation: 05/02/2021,
, , Revision: 4, Authorised, Last updated: 01/12/2023
-
List item
Human medicine European public assessment report (EPAR): Hulio (updated)
adalimumab, Hidradenitis Suppurativa; Psoriasis; Uveitis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic
Date of authorisation: 17/09/2018,, Revision: 16, Authorised, Last updated: 01/12/2023
-
List item
Human medicine European public assessment report (EPAR): Dovprela (previously Pretomanid FGK) (updated)
Pretomanid, Tuberculosis, Multidrug-Resistant
Date of authorisation: 31/07/2020,, 
, Revision: 9, Authorised, Last updated: 01/12/2023
-
List item
Human medicine European public assessment report (EPAR): Adcetris (updated)
Brentuximab vedotin, Lymphoma, Non-Hodgkin; Hodgkin Disease
Date of authorisation: 25/10/2012,, Revision: 35, Authorised, Last updated: 01/12/2023
-
List item
Human medicine European public assessment report (EPAR): Otezla (updated)
apremilast, Arthritis, Psoriatic; Psoriasis
Date of authorisation: 15/01/2015, Revision: 21, Authorised, Last updated: 01/12/2023 -
List item
Human medicine European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva (updated)
COVID-19 vaccine (inactivated, adjuvanted, adsorbed), COVID-19 virus infection
Date of authorisation: 24/06/2022,, Revision: 6, Withdrawn, Last updated: 01/12/2023
-
List item
Human medicine European public assessment report (EPAR): Plavix (updated)
clopidogrel hydrogen sulfate, Stroke; Peripheral Vascular Diseases; Atrial Fibrillation; Myocardial Infarction; Acute Coronary Syndrome
Date of authorisation: 15/07/1998, Revision: 50, Authorised, Last updated: 01/12/2023 -
List item
Human medicine European public assessment report (EPAR): Cialis (updated)
tadalafil, Erectile Dysfunction
Date of authorisation: 12/11/2002, Revision: 32, Authorised, Last updated: 01/12/2023 -
List item
Human medicine European public assessment report (EPAR): Ozawade (updated)
pitolisant, Sleep Apnea, Obstructive
Date of authorisation: 01/09/2021, Revision: 3, Authorised, Last updated: 01/12/2023 -
List item
Human medicine European public assessment report (EPAR): Ocaliva (updated)
Obeticholic acid, Liver Cirrhosis, Biliary
Date of authorisation: 12/12/2016,, , 
, Revision: 17, Authorised, Last updated: 30/11/2023
-
List item
Human medicine European public assessment report (EPAR): Praluent (updated)
Alirocumab, Dyslipidemias
Date of authorisation: 23/09/2015, Revision: 21, Authorised, Last updated: 30/11/2023 -
List item
Human medicine European public assessment report (EPAR): Xelevia (updated)
sitagliptin, Diabetes Mellitus, Type 2
Date of authorisation: 21/03/2007, Revision: 39, Authorised, Last updated: 30/11/2023 -
List item
Human medicine European public assessment report (EPAR): Rubraca (updated)
rucaparib camsylate, Ovarian Neoplasms
Date of authorisation: 23/05/2018,
, , Revision: 15, Authorised, Last updated: 30/11/2023
-
List item
Human medicine European public assessment report (EPAR): Kalydeco (updated)
ivacaftor, Cystic Fibrosis
Date of authorisation: 23/07/2012,
, Revision: 38, Authorised, Last updated: 30/11/2023
-
List item
Human medicine European public assessment report (EPAR): Inaqovi (updated)
cedazuridine, decitabine, Leukemia, Myeloid
Date of authorisation: 15/09/2023,, Authorised, Last updated: 30/11/2023
-
List item
Human medicine European public assessment report (EPAR): Yuflyma (updated)
adalimumab, Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Crohn Disease; Arthritis, Juvenile Rheumatoid
Date of authorisation: 11/02/2021,, Revision: 12, Authorised, Last updated: 30/11/2023
-
List item
Human medicine European public assessment report (EPAR): Ventavis (updated)
iloprost, Hypertension, Pulmonary
Date of authorisation: 15/09/2003, Revision: 30, Authorised, Last updated: 30/11/2023 -
List item
Human medicine European public assessment report (EPAR): Soliris (updated)
Eculizumab, Hemoglobinuria, Paroxysmal
Date of authorisation: 20/06/2007,, , Revision: 36, Authorised, Last updated: 30/11/2023
-
List item
Human medicine European public assessment report (EPAR): Thalidomide BMS (previously Thalidomide Celgene) (updated)
Thalidomide, Multiple Myeloma
Date of authorisation: 16/04/2008, Revision: 31, Authorised, Last updated: 30/11/2023 -
List item
Human medicine European public assessment report (EPAR): Abevmy (updated)
bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 21/04/2021,, , Revision: 7, Authorised, Last updated: 30/11/2023
-
List item
Human medicine European public assessment report (EPAR): Evusheld (updated)
tixagevimab, cilgavimab, COVID-19 virus infection
Date of authorisation: 25/03/2022,, Revision: 6, Authorised, Last updated: 30/11/2023
-
List item
Human medicine European public assessment report (EPAR): Neuraceq (updated)
florbetaben (18F), Radionuclide Imaging; Alzheimer Disease
Date of authorisation: 20/02/2014, Revision: 20, Authorised, Last updated: 30/11/2023